There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD38


Brief Information

Name:Lymphocyte differentiation antigen CD38
Target Synonym:EC:,2-Phospho-Cyclic-ADP-Ribose Transferase,Cyclic ADP-Ribose Hydrolase 1,2-Phospho-ADP-Ribosyl Cyclase,NAD(+) Nucleosidase,CD38 Antigen (P45),2-Phospho-ADP-Ribosyl Cyclase/2-Phospho-Cyclic-ADP-Ribose Transferase,Ecto-Nicotinamide Adenine Dinucleot
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data


Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

FITC-Labeled Human CD38, Fc TagFITC-Labeled Human CD38, Fc Tag (Cat. No. CD8-HF255) ELISA bioactivity

Immobilized Anti-CD38 Antibody (Daratumumab), Human IgG1 at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human CD38, Fc Tag (Cat. No. CD8-HF255) with a linear range of 0.078-0.625 μg/mL (QC tested).

Customer Reviews

Synonym Name

CD38,T10,cADPr hydrolase 1


CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Daratumumab/Hyaluronidase-fihj Approved Janssen Global Services Llc Darzalex Faspro United States Amyloidosis Janssen Biotech Inc 2020-05-01 Multiple Myeloma; Amyloidosis Details
Isatuximab SAR-650984 Approved Immunogen Inc Sarclisa Japan Multiple Myeloma Sanofi 2020-03-02 Bone Marrow Neoplasms; Carcinoma, Transitional Cell; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Hemolytic, Autoimmune; Colorectal Neoplasms; Leukemia, Myeloid, Acute Details
Daratumumab JNJ-54767414 Approved Janssen Global Services Llc Darzalex, 兆珂, 兆珂速 Mainland China Multiple Myeloma Janssen-Cilag International Nv 2015-11-16 Lymphoma, B-Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Smoldering Multiple Myeloma; Multiple Myeloma; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Amyloidosis; Lymphoma, Non-Hodgkin; Lymphoma; Large intestine neoplasm Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase 1 Clinical Wuhan Union Hospital, Shengyan Pharmaceutical Technology Multiple Myeloma Details
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) Phase 1 Clinical Celularity, Sorrento Therapeutics Multiple Myeloma Details
CART-38 CART-38 Phase 2 Clinical The First Affiliated Hospital Of Soochow University Leukemia, Myeloid, Acute Details
Recombinant human anti-CD38 momoclonal antibody(Sumgen) SG301; SG-301 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Multiple Myeloma Details
64Cu-DOTA-daratumumab Phase 1 Clinical City Of Hope National Medical Center Multiple Myeloma Details
211At-OKT10-B10 Phase 1 Clinical Fred Hutchinson Cancer Research Center Multiple Myeloma Details
CID-103 CID-103; TSK011010 Phase 1 Clinical Tusk Therapeutics Ltd Hematologic Neoplasms; Multiple Myeloma Details
TAK-169 TAK-169 Phase 1 Clinical Molecular Templates Multiple Myeloma Details
AMG-424 AMG-424 Phase 1 Clinical Amgen Inc, Xencor Multiple Myeloma Details
TAK-573 TAK-573; TEV-48573 Phase 2 Clinical Takeda Pharmaceutical Co Ltd Multiple Myeloma; Melanoma Details
GBR-1342 GBR-1342; ISB-1342 Phase 1 Clinical Glenmark Pharmaceuticals Ltd Multiple Myeloma Details
MOR-202 TJ-202; MOR-202; MOR-03087 Phase 3 Clinical Morphosys Ag Multiple Myeloma; Glomerulonephritis, Membranous; Glomerulonephritis Details
STI-6129 STI-6129 Phase 1 Clinical Sorrento Therapeutics Immunoglobulin Light-chain Amyloidosis Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
89Zr-DFO-daratumumab Phase 2 Clinical Memorial Sloan Kettering Cancer Center Details
TAK-079 TAK-079 Phase 2 Clinical Takeda Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic Details
Y-150 Y-150; Y150 Phase 1 Clinical Wuhan Yzy Biopharma, CSPC Pharmaceutical Group Ltd Multiple Myeloma Details
CM-313 CM-313 Phase 1 Clinical Connaught Biomedical Technology (Chengdu) Co Ltd Hematologic Neoplasms; Multiple Myeloma; Lymphoma Details

This web search service is supported by Google Inc.